Hoth TherapeuticsHOTH
HOTH
About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Employees: 3
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
18% more funds holding
Funds holding: 11 [Q2] → 13 (+2) [Q3]
1.38% less ownership
Funds ownership: 6.69% [Q2] → 5.31% (-1.38%) [Q3]
10% less capital invested
Capital invested by funds: $327K [Q2] → $293K (-$33.3K) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
158%
upside
Avg. target
$4.50
190%
upside
High target
$5
223%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 39% 1-year accuracy 71 / 182 met price target | 223%upside $5 | Buy Maintained | 7 Jan 2025 |
HC Wainwright & Co. Raghuram Selvaraju 40% 1-year accuracy 125 / 312 met price target | 158%upside $4 | Buy Reiterated | 4 Nov 2024 |
Financial journalist opinion
Based on 5 articles about HOTH published over the past 30 days
Neutral
PRNewsWire
6 days ago
Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries
The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt.
Positive
Zacks Investment Research
6 days ago
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
Positive
Benzinga
1 week ago
Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?
On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients.
Neutral
PRNewsWire
1 week ago
Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities
Highlights: 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy with Zero Dose Reductions NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. Exceptional Patient Outcomes: Data from the open-label portion of the CLEER-001 trial demonstrated remarkable success: 100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.
Neutral
PRNewsWire
2 weeks ago
Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK , Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin. "As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth.
Neutral
PRNewsWire
2 months ago
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology.
Neutral
PRNewsWire
3 months ago
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
Neutral
PRNewsWire
3 months ago
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. NEW YORK, Sept.
Positive
Zacks Investment Research
4 months ago
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Charts implemented using Lightweight Charts™